

ESM Table 2

Table 2. Gene expression of SMC and EC lineage genes in cultured CACs.

Gene	Type 2 diabetes without MVD	Type 2 diabetes with PAD	Type 2 diabetes with CAD	Healthy control	Non-type 2 diabetes with PAD	Non-type 2 diabetes with CAD	p-value
SMC							
<i>ACTA2</i>	1.4 ± 0.4	0.8 ± 0.1 Δ	0.6 ± 0.1 Δ	1.0 ± 0.3	0.4 ± 0.2	0.7 ± 0.2 Δ	NS
<i>SMT</i>	2.0 ± 0.6	1.9 ± 0.6	1.6 ± 0.4	1.0 ± 0.2	1.1 ± 0.3	1.6 ± 0.3	NS
<i>SRF</i>	1.1 ± 0.2	1.0 ± 0.1	1.0 ± 0.6	1.0 ± 0.1	0.8 ± 0.1	1.1 ± 0.2	NS
<i>KLF4</i>	1.4 ± 0.4	1.2 ± 0.2	1.7 ± 0.6	1.0 ± 0.2	0.9 ± 0.2	0.9 ± 0.2	NS
<i>SMAD4</i>	1.5 ± 0.2	1.1 ± 0.1	1.1 ± 0.1	1.0 ± 0.04	0.9 ± 0.04 ^a	1.0 ± 0.03	<0.05
<i>TGFB1</i>	1.3 ± 0.2	1.3 ± 0.1	1.7 ± 0.2	1.0 ± 0.1	1.0 ± 0.1	1.1 ± 0.04 Δ	NS
<i>TGFBRI</i>	1.5 ± 0.4	1.1 ± 0.1	1.1 ± 0.2	1.0 ± 0.1	1.0 ± 0.1	1.1 ± 0.2	NS
<i>TGFBRI2</i>	1.3 ± 0.2	0.9 ± 0.1	1.0 ± 0.1	1.0 ± 0.1	0.8 ± 0.1	1.1 ± 0.1	NS
<i>BMP4</i>	1.1 ± 0.4	0.5 ± 0.1	0.3 ± 0.1	1.0 ± 0.3	0.4 ± 0.1	0.5 ± 0.1	NS
<i>BMP6</i>	3.4 ± 1.3	5.9 ± 1.4 ^b	0.7 ± 0.4 Δ	1.0 ± 0.4	1.3 ± 0.4	4.0 ± 1.8	<0.05
<i>PDGFBB</i>	1.7 ± 0.3	1.4 ± 0.3	1.0 ± 0.3	1.0 ± 0.2	1.2 ± 0.1	1.2 ± 0.2	NS
EC							
<i>KDR</i>	0.5 ± 0.2 Δ	0.2 ± 0.1	0.5 ± 0.2	1.0 ± 0.4	0.3 ± 0.1	0.3 ± 0.2	NS
<i>VEGFA</i>	0.9 ± 0.2 Δ	1.1 ± 0.1	1.3 ± 0.2	1.0 ± 0.2	1.2 ± 0.3	1.5 ± 0.4	NS
<i>NOS3</i>	0.8 ± 0.3 Δ	1.4 ± 0.5	0.4 ± 0.1 Δ	1.0 ± 0.3	0.8 ± 0.2 Δ	1.1 ± 0.2	NS
<i>CDH5</i>	2.9 ± 1.0	8.3 ± 3.6	1.5 ± 0.6 Δ	1.0 ± 0.5	1.6 ± 0.4	1.4 ± 0.7	NS
<i>PECAMI</i>	2.0 ± 0.7	1.0 ± 0.1	1.0 ± 0.1	1.0 ± 0.1	0.9 ± 0.1	1.1 ± 0.1	NS

Data are expressed as relative mRNA expression +/- SEM compared to the healthy control group. N=6 per group unless indicated by Δ (N=5). *ACTA2*, α-Smooth muscle actin; *SMT*, Smoothelin, *SRF*, Serum response factor; *KLF4*, Krüppel-like factor 4; *SMAD4*; Mothers against decapentaplegic homolog 4; *TGFB1*, Transforming growth factor-β; *TGFBRI*, Transforming growth factor-β receptor 1; *TGFBRI2*, Transforming growth factor-β receptor 2; *BMP4*, Bone-morphogenetic protein 4; *BMP6*, Bone-morphogenetic protein 6; *PDGFBB*, Platelet-derived growth factor-bb; *KDR*, Kinase domain receptor; *VEGFA*, Vascular endothelial growth factor A; *NOS3*, Endothelial nitric oxide synthase; *CDH5*, *Vascular endothelial cadherin*; *PECAMI*; Platelet endothelial cell adhesion molecule 1

Statistically significant with ANOVA compared to:

^anon-T2DM with PAD vs. non-T2DM with CAD

^bT2DM with PAD vs. T2DM with CAD.